30% of the 382m diabetics globally
will develop nephropathy.

Now enrolling Phase 2 clinical trial

Our novel scientific approach
slows the progression of diabetic
kidney disease.


Review the science

A long-term, committed
partnership speaks to the
value of our work.

Vascular Pharmaceuticals is addressing the complications of diabetes

Vascular Pharmaceuticals is pioneering a new approach to treat one of the most common complications of diabetes, diabetic nephropathy. This type of kidney disease affects individuals living with Type 1 and Type 2 diabetes, and there is currently no cure.

We aspire to help people with diabetes live longer, healthier lives. Our lead candidate, VPI-2960B, is in Phase 2 clinical trials. Studies conducted in animal models of diabetic nephropathy have shown that VPI-2690B may stop and even reverse the progression of diabetic nephropathy. We are committed to exploring the benefits of this potential breakthrough for diabetics who currently lack effective treatment options.

Information for patients •>>

News, Events and Publications
03/02/15 Vascular Pharmaceuticals, Inc. Completes $9.0 Million Expansion of Series A Financing •>>
11/14/14 Vascular Pharmaceuticals, Inc. Initiates Phase 2 Clinical Trial of VPI-2690B for Diabetic Nephropathy •>>
09/12/12 Vascular Pharmaceuticals, Inc. Completes $16 Million Equity Financing, Signs Agreement with Janssen Biotech, Inc. •>>